Jose C Alvarez-Cermeno
Overview
Explore the profile of Jose C Alvarez-Cermeno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toboso I, Tejeda-Velarde A, Alvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, et al.
Front Neurol
. 2021 Jan;
11:579438.
PMID: 33408681
We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36...
2.
Perez-Perez S, Dominguez-Mozo M, Alonso-Gomez A, Medina S, Villarrubia N, Fernandez-Velasco J, et al.
PeerJ
. 2020 Nov;
8:e10220.
PMID: 33240608
Background: Gut microbiota has been related to multiple sclerosis (MS) etiopathogenesis. Short-chain fatty acids (SCFA) are compounds derived from microbial metabolism that have a role in gut-brain axis. Objectives: To...
3.
Meca-Lallana J, Ayuso T, Martinez-Yelamos S, Duran C, Contreras Martin Y, Herrera Navarro N, et al.
Eur Neurol
. 2020 Mar;
83(1):25-33.
PMID: 32187609
Background: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter, observational study, in...
4.
Zhou Y, Claflin S, Stankovich J, van der Mei I, Simpson Jr S, Roxburgh R, et al.
Mult Scler
. 2019 Nov;
26(13):1765-1774.
PMID: 31668127
Background: The Multiple Sclerosis Severity Score (MSSS) is a widely used measure of the disability progression rate. However, the global MSSS may not be the best basis for comparison between...
5.
Bridel C, van Wieringen W, Zetterberg H, Tijms B, Teunissen C, Alvarez-Cermeno J, et al.
JAMA Neurol
. 2019 Jun;
76(9):1035-1048.
PMID: 31206160
Importance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage....
6.
Medina S, Sainz De La Maza S, Villarrubia N, Alvarez-Lafuente R, Costa-Frossard L, Arroyo R, et al.
Ann Clin Transl Neurol
. 2019 Mar;
6(2):355-363.
PMID: 30847367
Objectives: Teriflunomide, a disease-modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down-regulates proliferation of activated lymphocytes. We aimed...
7.
Sainz De La Maza S, Medina S, Villarrubia N, Costa-Frossard L, Monreal E, Tejeda-Velarde A, et al.
J Neurol Sci
. 2019 Jan;
398:4-8.
PMID: 30658226
Background: Lymphopenia is a major concern in MS patients treated with dimethyl-fumarate (DMF) as it increases the risk of progressive multifocal leukoencephalopathy. Objective: To identify factors associated with lymphopenia in...
8.
Malhotra S, Villar L, Costa C, Midaglia L, Cubedo M, Medina S, et al.
J Neuroinflammation
. 2018 Oct;
15(1):296.
PMID: 30367633
Background: Recent studies in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (MS), suggest an involvement of the histone methyltransferase enhancer of zeste 2 polycomb repressive complex 2 subunit...
9.
Gil-Varea E, Urcelay E, Vilarino-Guell C, Costa C, Midaglia L, Matesanz F, et al.
J Neuroinflammation
. 2018 Sep;
15(1):265.
PMID: 30217166
Background: It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses...
10.
Matute-Blanch C, Villar L, Alvarez-Cermeno J, Rejdak K, Evdoshenko E, Makshakov G, et al.
Brain
. 2018 Feb;
141(4):1085-1093.
PMID: 29452342
The prognostic role of cerebrospinal fluid molecular biomarkers determined in early pathogenic stages of multiple sclerosis has yet to be defined. In the present study, we aimed to investigate the...